These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 14742735

  • 1. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
    Dogné JM, Hanson J, de Leval X, Kolh P, Tchana-Sato V, de Leval L, Rolin S, Ghuysen A, Segers P, Lambermont B, Masereel B, Pirotte B.
    J Pharmacol Exp Ther; 2004 May; 309(2):498-505. PubMed ID: 14742735
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J, Rolin S, Reynaud D, Qiao N, Kelley LP, Reid HM, Valentin F, Tippins J, Kinsella BT, Masereel B, Pace-Asciak C, Pirotte B, Dogné JM.
    J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
    [Abstract] [Full Text] [Related]

  • 3. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism.
    Ghuysen A, Lambermont B, Dogné JM, Kolh P, Tchana-Sato V, Morimont P, Magis D, Hanson J, Segers P, D'Orio V.
    J Pharmacol Exp Ther; 2004 Sep; 310(3):964-72. PubMed ID: 15121765
    [Abstract] [Full Text] [Related]

  • 4. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis.
    Rolin S, Petein M, Tchana-Sato V, Dogne JM, Benoit P, Lambermont B, Ghuysen A, Kolh P, Masereel B.
    J Pharmacol Exp Ther; 2003 Jul; 306(1):59-65. PubMed ID: 12721335
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents.
    de Leval X, Dassesse T, Dogné JM, Waltregny D, Bellahcène A, Benoit V, Pirotte B, Castronovo V.
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1057-67. PubMed ID: 16720756
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor.
    Ghuysen A, Dogné JM, Chiap P, Rolin S, Masereel B, Lambermont B, Kolh P, Tchana-Sato V, Hanson J, D'Orio V.
    Cardiovasc Drug Rev; 2005 Sep; 23(1):1-14. PubMed ID: 15867944
    [Abstract] [Full Text] [Related]

  • 10. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
    Vilahur G, Casaní L, Badimon L.
    Thromb Haemost; 2007 Sep; 98(3):662-9. PubMed ID: 17849057
    [Abstract] [Full Text] [Related]

  • 11. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
    Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J.
    J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
    [Abstract] [Full Text] [Related]

  • 12. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
    Jin YR, Cho MR, Lee KS, Lee JJ, Lim Y, Han XH, Oh KW, Hong JT, Yoo HS, Yun YP.
    Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531.
    Dogné JM, Rolin S, de Leval X, Benoit P, Neven P, Delarge J, Kolh P, Damas J, David JL, Masereel B.
    Cardiovasc Drug Rev; 2001 Sep; 19(2):87-96. PubMed ID: 11484064
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
    Soyka R, Guth BD, Weisenberger HM, Luger P, Müller TH.
    J Med Chem; 1999 Apr 08; 42(7):1235-49. PubMed ID: 10197967
    [Abstract] [Full Text] [Related]

  • 18. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
    De Clerck F, Beetens J, Van de Water A, Vercammen E, Janssen PA.
    Thromb Haemost; 1989 Feb 28; 61(1):43-9. PubMed ID: 2526385
    [Abstract] [Full Text] [Related]

  • 19. Effects of BM-573, a thromboxane A2 modulator on systemic hemodynamics perturbations induced by U-46619 in the pig.
    Tchana-Sato V, Dogné JM, Lambermont B, Ghuysen A, Magis D, Morimont P, Hanson J, D'Orio V, Limet R, Kolh P.
    Prostaglandins Other Lipid Mediat; 2005 Dec 28; 78(1-4):82-95. PubMed ID: 16303607
    [Abstract] [Full Text] [Related]

  • 20. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice.
    Cyrus T, Yao Y, Ding T, Dogné JM, Praticò D.
    Eur J Pharmacol; 2007 Apr 30; 561(1-3):105-11. PubMed ID: 17306791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.